Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients

Abstract

Background Irritable bowel syndrome (IBS) is a common gastrointestinal disorder, which still lacks effective therapy. We aimed to investigate the effects of a novel formulation of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 with vitamin B6 (LBB) on symptoms, intestinal permeability, cultivable bacteria and metabolome in IBS subjects. Materials and methods Twenty‐five IBS patients (Rome IV criteria) (M:F = 8:17; age 48 years ± 11 SD) were randomized to treatment (LBB) or placebo (one month each) in a crossover randomized double‐blind controlled trial. Symptoms, intestinal habits, disease severity, intestinal permeability and intestinal microbiota were analysed at 0, 30, 45 and 60 days. Results Percentage decrease from baseline of abdominal pain (−48.8% vs −3.5%), bloating (−36.35% vs +7.35%) and severity of disease (−30.1% vs −0.4%) was significantly (P < .0001) greater with LBB than placebo, respectively. In IBS‐D patients, the improvement from baseline of Bristol score was more consistent with LBB (from 6 ± 0.4 to 4.3 ± 1.1, P < .00001) than placebo (from 6.2 ± 0.7 to 5.3 ± 1.1, P = .04). In IBS‐C patients, Bristol score tended to improve from baseline after LBB (2.6 ± 1.1 vs 3.2 ± 0.5, P = .06). LBB significantly improved the percentage of sucralose recovery (colonic permeability) (1.86 ± 0.1 vs 1.1 ± 0.2, P = .01). During treatment, presumptive lactic acid bacteria and bifidobacteria, relative abundance of propanoic, butanoic, pentanoic acids and hydrocarbons increased, while phenol decreased. Conclusions The novel formulation of B. longum BB536 and L. rhamnosus HN001 with B6 vitamin improves symptoms and severity of disease, restores intestinal permeability and gut microbiota in IBS patients.

Increased Colonic Permeability and Lifestyles as Contributing Factors to Obesity and Liver Steatosis

“…These aspects should be specifically explored in future studies linking the role of gut microbiome and bacterial products, with local effects on the dynamics of epithelial barriers, and therefore intestinal permeability. Notably, in irritable bowel syndrome (IBS) patients, we recently found that oral administration of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 with vitamin B6 improved symptoms, severity of disease, while restoring intestinal permeability, modifying the composition of gut microbiota [59].…”

The Role of Intestinal Microbiota and Mast Cell in a Rat Model of Visceral Hypersensitivity

“…48 Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 restored intestinal permeability and gut microbiota in IBS patients. 49 Prevotella had a negative association with pain in IBS patients. 24 Clostridium sensu stricto 1 was a representative species of Clostridium and could produce short-chain fatty acids (SCFAs).…”

Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report

“…A likely explanation for these findings could lie in a prolonged period of exposure to PAMPs. More recently, it has been reported that treatment with B. longum BB536 and Lactobacillus rhamnosus HN001 with vitamin B6, compared to placebo, significantly improved GI symptoms and restored intestinal permeability in patients with IBS, as deduced by the improved percentage of sucralose recovery [53]. To date, very few studies have investigated serum zonulin concentration in patients with IBS.…”